Form 4: USANA Director Sells All Common Stock Holdings

USANA Health Sciences Director Gilbert A. Fuller reported the sale of 1,058 shares of common stock at $17 per share, reducing his direct beneficial ownership to zero.

Summary

• Director Gilbert A. Fuller of USANA Health Sciences Inc. reported a transaction pursuant to a Rule 10b5-1 plan.
• The transaction involved the disposition (sale) of 1,058 shares of Common Stock.
• The shares were sold at a price of $17 per share.
• Following this transaction, Gilbert A. Fuller directly beneficially owns 0 shares of USANA Health Sciences Inc.
• The transaction date is listed as March 20, 2026.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative signal due to a director completely divesting their direct common stock holdings, which could imply a lack of long-term confidence in the company's future, even if pre-planned.

Negatives

• A director, Gilbert A. Fuller, sold all 1,058 shares of his directly held common stock in USANA Health Sciences Inc. at $17 per share, reducing his direct beneficial ownership to zero.
• While executed under a Rule 10b5-1 plan, the complete divestment by a director can still be interpreted by the market as a lack of long-term alignment or confidence.

Risks

• Despite being executed under a Rule 10b5-1 plan, the complete divestment of a director's direct equity holdings can be perceived negatively by the market, potentially signaling a lack of long-term confidence in the company's future prospects by an insider.

Future Outlook

The filing does not contain forward-looking statements or guidance.

Industry Context

StockSavvy.ai notes that insider selling, particularly a full divestment by a director, can sometimes be viewed with caution by investors, as it might suggest an insider believes the stock is fully valued or faces future headwinds, contrasting with typical industry trends where insiders often hold significant stakes to align with shareholder interests. The execution under a 10b5-1 plan indicates the transaction was pre-scheduled, which can mitigate some immediate negative interpretations.

Comparison to Industry Standards

• A director selling their entire direct stake is an uncommon event compared to typical insider transactions, which often involve partial sales for liquidity or tax planning.
• For example, in the health sciences industry, directors often maintain a substantial equity position to demonstrate long-term commitment, unlike this complete divestment, even if pre-planned under a 10b5-1 arrangement.

Stakeholder Impact

• Shareholders: May interpret the director's complete divestment as a negative signal regarding long-term prospects, potentially impacting investor sentiment and stock price, despite the transaction being pre-planned under a 10b5-1 arrangement.

Key Dates

Recommendation

The complete divestment of all directly held common stock by a director, Gilbert A. Fuller, at $17 per share, even if executed under a Rule 10b5-1 plan, removes a key insider's equity alignment with shareholders. While the pre-planned nature mitigates concerns about opportunistic selling, the absence of any direct ownership from a director can be interpreted as a long-term negative signal regarding the company's future value, warranting a sell recommendation.

Keywords

USANA Health Sciences, USNA, Form 4, Insider Trading, Stock Sale, Director, Gilbert A. Fuller, Beneficial Ownership, 10b5-1 Plan